Literature DB >> 3700691

Inhibition of tolbutamide elimination by cimetidine but not ranitidine.

E W Cate, J F Rogers, J R Powell.   

Abstract

This study was designed to compare the effects of equivalent therapeutic doses of two H2 antagonists, cimetidine and ranitidine, on tolbutamide pharmacokinetics. Twelve healthy men were given a 1-g oral dose of tolbutamide on three occasions. Subjects were randomly assigned to three treatments in a crossover fashion: cimetidine 1,200 mg/d, ranitidine 300 mg/d, and placebo. Cimetidine significantly increased the tolbutamide area under the plasma concentration-time curve by 20% (range, -5% to 42%), increased the elimination half-life by 17%, and decreased the carboxytolbutamide:tolbutamide plasma ratio from 0.042 to 0.036. Ranitidine did not significantly alter tolbutamide pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700691     DOI: 10.1002/j.1552-4604.1986.tb03540.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

2.  Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers.

Authors:  E Tanaka; K Nakamura
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

3.  Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism.

Authors:  G I Adebayo; H A Coker
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 5.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 6.  Drug-induced hypoglycaemia: an update.

Authors:  Chaker Ben Salem; Neila Fathallah; Houssem Hmouda; Kamel Bouraoui
Journal:  Drug Saf       Date:  2011-01-01       Impact factor: 5.606

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

8.  Co-regulation of phenytoin and tolbutamide metabolism in humans.

Authors:  W Tassaneeyakul; M E Veronese; D J Birkett; C J Doecke; M E McManus; L N Sansom; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

9.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

Authors:  D J Back; J F Tjia; J Karbwang; J Colbert
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

10.  Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.

Authors:  D J Back; J Tjia; H Mönig; E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.